Treatment of Renal Disease in ANCA Vasculitis
- Jan 22, 2025
- 3:00PM TO 4:00 PM
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
About the Case Presentation
The treatment of renal disease in ANCA-associated vasculitis (AAV) typically involves a combination of immunosuppressive therapies to control inflammation and prevent further kidney damage. First-line treatment often includes high-dose corticosteroids and cyclophosphamide or rituximab, both of which help to induce remission by targeting the underlying immune system dysfunction. In cases of kidney failure or rapidly progressive glomerulonephritis, plasmapheresis may be used to remove circulating autoantibodies. Once remission is achieved, maintenance therapy with lower doses of immunosuppressants, such as azathioprine or mycophenolate mofetil, is used to prevent relapses and preserve kidney function.
About the Speaker
Dr. Amitabh Kulkarni
Head of Department, Nephrology, NMC Speciality Hospital, Dubai
Dr. Amitabh Kulkarni is an experienced Consultant Nephrologist with over 11 years of expertise in the field. He has been practicing at NMC Specialty Hospital in Dubai since November 2013, specializing in risk management, renal transplant, and a wide range of nephrology skills. Prior to this, Dr. Kulkarni worked at Apollo Hospitals in Hyderabad from May 2012 to October 2013, and at Narayana Hrudayalaya Hospital from October 2010 to April 2012, where he honed his skills in advanced nephrology care. He also completed a Clinical Fellowship in Nephrology at The Ottawa Hospital in Ontario, Canada, from May 2008 to June 2010. Dr. Kulkarni’s extensive training and clinical experience make him a highly regarded specialist in nephrology and kidney transplantation.